Apogee Therapeutics, Inc. corporate insiders have only been selling lately: four insiders unloaded about $174 million of stock over 12 months, with no open-market purchases.
Keep in mind most insider selling is routine — stock-based pay has to be converted to cash at some point.
7 quarters in a row of net selling by insiders. Insiders bought in 0 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Aug 7, 2026 | Dambkowski Carl | Executive Officer | Sell | 5,500 | $134.17 | $738K | SEC |
| Jul 10, 2026 | HENDERSON MICHAEL THOMAS | CEO | Sell | 20,000 | $133.63 | $2.7M | SEC |
| Jul 2, 2026 | Dambkowski Carl | Executive Officer | Sell | 5,500 | $132.74 | $730K | SEC |
| Jun 24, 2026 | Dambkowski Carl | Executive Officer | Sell | 26,400 | $132.60 | $3.5M | SEC |
| Jun 24, 2026 | HENDERSON MICHAEL THOMAS | CEO | Sell | 80,000 | $132.54 | $10.6M | SEC |
| Jun 12, 2026 | HENDERSON MICHAEL THOMAS | CEO | Sell | 7,654 | $82.78 | $634K | SEC |
| Jun 12, 2026 | HENDERSON MICHAEL THOMAS | CEO | Sell | 1,080 | $84.18 | $91K | SEC |
| Jun 12, 2026 | HENDERSON MICHAEL THOMAS | CEO | Sell | 6,770 | $82.21 | $557K | SEC |
| Jun 12, 2026 | HENDERSON MICHAEL THOMAS | CEO | Sell | 1,577 | $85.19 | $134K | SEC |
| Jun 12, 2026 | HENDERSON MICHAEL THOMAS | CEO | Sell | 2,305 | $86.27 | $199K | SEC |
| Jun 12, 2026 | HENDERSON MICHAEL THOMAS | CEO | Sell | 614 | $86.89 | $53K | SEC |
| Jun 5, 2026 | Dambkowski Carl | Executive Officer | Sell | 5,500 | $78.71 | $433K | SEC |
| May 15, 2026 | HENDERSON MICHAEL THOMAS | CEO | Sell | 18,659 | $82.05 | $1.5M | SEC |
| May 15, 2026 | HENDERSON MICHAEL THOMAS | CEO | Sell | 1,341 | $82.58 | $111K | SEC |
| May 8, 2026 | Dambkowski Carl | Executive Officer | Sell | 3,700 | $83.92 | $311K | SEC |
In the last 12 months Apogee Therapeutics, Inc. insiders made open-market purchases worth about $0 and sales worth about $174 million. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in APGE was filed on 2026-08-07.
No congressional trades in APGE were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).